Quick Answer
ADIAL PHARMACEUTICALS, INC. reported Diluted EPS of $11.93 per share (loss) for fiscal year 2025.
ADIAL PHARMACEUTICALS, INC. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$11.93 | +82.5% |
| 2024 | -$68.01 | -1789.2% |
| 2023 | -$3.60 | +71.7% |
| 2022 | -$12.71 | -1122.1% |
| 2021 | -$1.04 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.08 | +78.9% | +55.6% |
| June 30, 2025 | -$0.18 | +69.5% | +47.1% |
| March 31, 2025 | -$0.34 | +84.5% | +10.5% |
| September 30, 2024 | -$0.38 | +67.8% | +35.6% |
| June 30, 2024 | -$0.59 | -161.5% | +73.1% |
| March 31, 2024 | -$2.19 | +20.4% | -85.6% |
| September 30, 2023 | -$1.18 | +60.9% | -222.9% |
| June 30, 2023 | $0.96 | +124.2% | +134.9% |
- ADIAL PHARMACEUTICALS, INC. showed an increase of +82.5% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, ADIAL PHARMACEUTICALS, INC.’s diluted eps has declined by 1047.1% (from $1.04 per share (loss) to $11.93 per share (loss)).
- The most recent figure is from ADIAL PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: